P53 in blind subterranean mole rats - Loss-of-function versus gain-of-function activities on newly cloned Spalax target genes

Oncogene

Volumn 26, Issue 17, 2007, Pages 2507-2512

  Avivi, A ^a   Ashur Fabian, O ^b,c   Joel, A ^a   Trakhtenbrot, L ^b,c   Adamsky, K ^b,c   Goldstein, I ^b,c   Amariglio, N ^b,c   Rechavi, G ^b,c   Nevo, E ^a  

^a UNIVERSITY OF HAIFA   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

apaf1; Hypoxia; mdm2; p53; Subterranean mole rat

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE INDUCTION; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; INTRON; MOLE RAT; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RAT;

ANIMALS; ANOXIA; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; GENE EXPRESSION REGULATION; HUMANS; MICE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RATS; SPALAX; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS; SPALAX;

EID: 34247093885     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210045     Document Type: Article

References (33)

1. Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G et al. (2004). Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci USA 101: 12236-12241.
2. Avivi A, Ashur-Fabian O, Amariglio N, Nevo E, Rechavi G. (2005a). p53 - a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat. Cell Cycle 4: 368-372.
3. Avivi A, Resnick MB, Nevo E, Joel A, Levy AP. (1999). Adaptive hypoxic tolerance in the subterranean mole rat Spalax ehrenbergi: the role of vascular endothelial growth factor. FEBS Lett 452: 133-140.
4. Avivi A, Shams I, Joel A, Lache O, Levy AP, Nevo E. (2005b). Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J 19: 1314-1316.
5. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. (1992). Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
6. Gagnebin J, Kovar H, Kajava AV, Estreicher A, Jug G, Monnier P, Iggo R. (1998). Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 16: 685-690.
7. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. (2003). Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23: 359-369.
8. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991). p53 mutations in human cancers. Science 253: 49-53.
10. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD et al. (2004). Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57: 504-512.
11. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. (2001). DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 20: 3449-3455.
12. Kinzler KW, Vogelstein B. (1996). Life (and death) in a malignant tumour. Nature 379: 19-20.
13. Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K et al. (2001). NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem 276: 49020-49027.
14. Klein G. (2004). Cancer, apoptosis, and nonimmune surveillance. Cell Death Differ 11: 13-17.
15. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D et al. (2006). Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29-33.
16. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
17. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK et al. (2004). Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36: 63-68.
18. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F et al. (2001). Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3: 552-558.
19. Nevo E. (1999). Mosaic Evolution of Subterranean Mammals: Regression, Progression and Global Convergence. Oxford University Press: Oxford.
20. Nevo E, Ivanitskaya E, Beiles A. (2001). Adaptive Radiation of Blind Subterranean Mole Rats. Backhuys: Leiden.
21. Oliver FJ, Marvel J, Collins MK, Lopez-Rivas A. (1993). Bcl-2 oncogene protects a bone marrow-derived pre-B-cell line from 5′-fluor,2′- deoxyuridine-induced apoptosis. Biochem Biophys Res Commun 194: 126-132.
22. Peters KG, De Vries C, Williams LT. (1993). Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 90: 8915-8919.
23. Resnick MA, Inga A. (2003). Functional mutants of the sequencespecific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934-9939.
24. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. (1998). Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 51: 55-61.
25. Rozenfeld-Granot G, Krishnamurthy J, Kannan K, Toren A, Amariglio N, Givol D et al. (2002). A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene 21: 1469-1476.
26. Ryan KM, Vousden KH. (1998). Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18: 3692-3698.
27. Shams I, Avivi A, Nevo E. (2004). Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci USA 101: 9698-9703.
28. Shams I, Nevo E, Avivi A. (2005a). Erythropoietin receptor spliced forms differentially expressed in blind subterranean mole rats. FASEB J 19: 1749-1751.
29. Shams I, Nevo E, Avivi A. (2005b). Ontogenetic expression of erythropoietin and hypoxia-inducible factor-1 alpha genes in subterranean blind mole rats. FASEB J 19: 307-309.
30. Shweiki D, Itin A, Soffer D, Keshet E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
31. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799.
32. Vousden KH, Lu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
33. Widmer HR, Hoppeler H, Nevo E, Taylor CR, Weibel ER. (1997). Working underground: respiratory adaptations in the blind mole rat. Proc Natl Acad Sci USA 94: 2062-2067.